Tecentriq

Nov 29, 2024

Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying NSCLC incidence all over the world. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The number of people living for at least five years after ...

Sep 23, 2024

Better late than never for FDA approval of the first subcutaneous PD-L1 inhibitor—Roche’s TECENTRIQ HYBREZA—after manufacturing delays disrupted the company’s initial launch plans last year. The FDA was originally set to decide on TECENTRIQ’s under-the-skin formulation in September, but Roche’s delivery technolo...

May 31, 2024

The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the pro...

Mar 23, 2021

Promega Biotech Ibérica Gains Recognition for COVID-19 Response in Spain Promega Biotech Ibérica has been heralded as the business leader in Spain for its COVID-19 response. The company’s innovative approach to deal with COVID-19 and pandemic has led La Razón, a daily newspaper based in Madrid, to felicitate the...

Dec 05, 2019

Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS. Reblozyl ((luspatercept-aamt) has recently been approved by the regulatory authority to cure a rare type of blood disorder, Beta-thalassemi...

Oct 10, 2017

Novo petitions FDA to require copies of Victoza to conduct clinical trials With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expiration, the insulin specialist has taken new steps to deter copies. The Danish drugmaker has filed a citizen petition arg...